CL2014000401A1 - Antigen binding protein specific for the alpha4beta7 heterodimer; and composition comprising it (div.sol.no 2306-11). - Google Patents

Antigen binding protein specific for the alpha4beta7 heterodimer; and composition comprising it (div.sol.no 2306-11).

Info

Publication number
CL2014000401A1
CL2014000401A1 CL2014000401A CL2014000401A CL2014000401A1 CL 2014000401 A1 CL2014000401 A1 CL 2014000401A1 CL 2014000401 A CL2014000401 A CL 2014000401A CL 2014000401 A CL2014000401 A CL 2014000401A CL 2014000401 A1 CL2014000401 A1 CL 2014000401A1
Authority
CL
Chile
Prior art keywords
heterodimer
div
sol
composition
antigen binding
Prior art date
Application number
CL2014000401A
Other languages
Spanish (es)
Inventor
Taruna Arora
Hailing Hsu
Ian Foltz
Frederick W Jacobsen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42224952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014000401(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2014000401A1 publication Critical patent/CL2014000401A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
CL2014000401A 2009-03-20 2014-02-18 Antigen binding protein specific for the alpha4beta7 heterodimer; and composition comprising it (div.sol.no 2306-11). CL2014000401A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16215409P 2009-03-20 2009-03-20
US30682910P 2010-02-22 2010-02-22

Publications (1)

Publication Number Publication Date
CL2014000401A1 true CL2014000401A1 (en) 2014-08-29

Family

ID=42224952

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2011002306A CL2011002306A1 (en) 2009-03-20 2011-09-16 Antibody or an antigen binding fragment thereof that specifically binds to the integrin heterodimer alpha4beta7; and composition that understands it.
CL2014000401A CL2014000401A1 (en) 2009-03-20 2014-02-18 Antigen binding protein specific for the alpha4beta7 heterodimer; and composition comprising it (div.sol.no 2306-11).
CL2014000400A CL2014000400A1 (en) 2009-03-20 2014-02-18 Antigen binding protein specific for the alpha4beta7 heterodimer; and composition comprising it (div.sol.no 2306-11).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2011002306A CL2011002306A1 (en) 2009-03-20 2011-09-16 Antibody or an antigen binding fragment thereof that specifically binds to the integrin heterodimer alpha4beta7; and composition that understands it.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2014000400A CL2014000400A1 (en) 2009-03-20 2014-02-18 Antigen binding protein specific for the alpha4beta7 heterodimer; and composition comprising it (div.sol.no 2306-11).

Country Status (26)

Country Link
US (6) US8444981B2 (en)
EP (1) EP2408816B1 (en)
JP (3) JP5498566B2 (en)
KR (2) KR101391472B1 (en)
CN (2) CN102388068B (en)
AR (1) AR075882A1 (en)
AU (1) AU2010226814B2 (en)
CA (2) CA2754113C (en)
CL (3) CL2011002306A1 (en)
CO (1) CO6501170A2 (en)
CR (1) CR20110544A (en)
EA (1) EA034783B1 (en)
ES (1) ES2751946T3 (en)
IL (4) IL214868A (en)
JO (1) JO3615B1 (en)
MA (1) MA33213B1 (en)
MX (4) MX357211B (en)
MY (2) MY162752A (en)
NZ (1) NZ595464A (en)
PE (2) PE20160553A1 (en)
SG (3) SG10201801337WA (en)
TN (1) TN2011000433A1 (en)
TW (2) TWI466681B (en)
UY (1) UY32501A (en)
WO (1) WO2010107752A2 (en)
ZA (1) ZA201107279B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116189C2 (en) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. COMPOSITION OF ANTI-α4β7 ANTIBODY
KR102493433B1 (en) * 2011-05-02 2023-01-27 밀레니엄 파머슈티컬스 인코퍼레이티드 FORMULATION FOR ANTI-α4β7 ANTIBODY
MX366936B (en) 2011-11-23 2019-07-31 Amgen Inc Administration of alpha4beta7 hetero-dimer-specific antibody.
EP3838923B1 (en) 2012-08-24 2024-05-01 The Regents of The University of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
CA2923145A1 (en) 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
JP6579097B2 (en) * 2014-02-28 2019-09-25 アステラス製薬株式会社 Bispecific antibody binding to novel human TLR2 and human TLR4
US10156562B2 (en) 2014-05-16 2018-12-18 Amgen Inc. Assay for detecting Th1 and Th2 cell populations
AU2015305894A1 (en) * 2014-08-22 2017-04-06 Sorrento Therapeutics, Inc. Antigen binding proteins that bind CXCR3
US10532051B2 (en) 2014-10-06 2020-01-14 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor 9 (CCR9) and anti-α4β7 integrin blocking antibodies
JP2017537105A (en) 2014-11-26 2017-12-14 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Bedolizumab for the treatment of Crohn's disease with fistula
MA41636A (en) 2015-03-06 2018-01-09 Millennium Pharm Inc METHOD OF TREATMENT OF PRIMITIVE SCLEROSANT CHOLANGITIS
EP3328994A4 (en) 2015-07-31 2019-04-17 Memorial Sloan-Kettering Cancer Center CD56 TARGETING ANTIGEN BINDING PROTEINS AND USES THEREOF
KR20240149974A (en) 2015-08-11 2024-10-15 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 Antibody
MX2018011025A (en) 2016-03-14 2019-01-10 Millennium Pharm Inc Methods of treating or preventing graft versus host disease.
KR102710759B1 (en) 2016-03-14 2024-09-25 밀레니엄 파머슈티컬스 인코퍼레이티드 How to prevent graft-versus-host disease
KR20210019491A (en) 2016-03-23 2021-02-22 서울대학교산학협력단 Antibodies which bind to SFTSV(Severe Fever with Thrombocytopenia Syndrome Virus) envelope glycoprotein and their use
WO2017165778A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
KR102414558B1 (en) 2016-04-18 2022-06-29 셀덱스 쎄라퓨틱스, 인크. Agonistic antibodies that bind to human CD40 and uses thereof
CA3027286A1 (en) 2016-06-12 2017-12-21 Millennium Pharmaceuticals, Inc. Method of treating inflammatory bowel disease
WO2018005519A2 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations
US20200131518A1 (en) 2017-03-14 2020-04-30 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
WO2018200818A2 (en) 2017-04-28 2018-11-01 Millennium Pharmaceuticals, Inc. Method of treating pediatric disorders
AU2019243848B2 (en) 2018-03-26 2025-01-02 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
WO2021062372A1 (en) 2019-09-26 2021-04-01 Amgen Inc. Methods of producing antibody compositions
EP4245373A3 (en) 2020-02-26 2023-12-20 VIR Biotechnology, Inc. Antibodies against sars-cov-2
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
KR20230087539A (en) 2020-10-15 2023-06-16 암젠 인크 Relative Unbound Glycans in Antibody Production Methods
JP2024510976A (en) * 2021-03-12 2024-03-12 アイカーン スクール オブ メディシン アット マウント サイナイ Neutralizing monoclonal antibody against BK virus
CA3222409A1 (en) 2021-06-07 2022-12-15 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
EP4413377A1 (en) 2021-10-05 2024-08-14 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
TW202504919A (en) 2023-05-30 2025-02-01 美商派拉岡醫療公司 Α4β7 integrin antibody compositions and methods of use
WO2024252368A2 (en) 2023-06-09 2024-12-12 Takeda Pharmaceutical Company Limited Methods and compositions for treating ulcerative colitis
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US714785A (en) 1901-07-03 1902-12-02 Benjamin M Davis Disinfecting apparatus.
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (en) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
EP0557300B1 (en) 1990-10-29 1997-11-19 Chiron Corporation Bispecific antibodies, method of production, and uses thereof
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (en) 1991-06-03 1992-12-10 Behringwerke Ag TETRAVALENT BISPECIFIC RECEPTORS, THEIR PRODUCTION AND USE
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JPH05244982A (en) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd Humanized b-b10
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
DE69332981T2 (en) 1992-10-23 2004-05-19 Immunex Corp., Seattle METHODS FOR THE PRODUCTION OF SOLUBLE, OLIGOMERIC PROTEINS
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
DE122006000043I1 (en) 1994-01-25 2007-02-15 Elan Pharm Inc Humanized antibodies to the leukocyte adhesion molecule vla-4
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
AU7676300A (en) * 1999-10-12 2001-04-23 Cambridge Antibody Technology Limited Human anti-adipocyte monoclonal antibodies and their use
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
WO2002076406A2 (en) * 2001-03-27 2002-10-03 Gershwin M Eric Antibodies against autoantigens of primary biliary cirrhosis and methods of making and using them
JPWO2002078779A1 (en) * 2001-03-27 2004-07-22 日本ゼオン株式会社 Medical guidewire
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
MEP18108A (en) 2002-08-19 2010-06-10 Astrazeneca Ab Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
TWI366570B (en) * 2004-01-09 2012-06-21 Pfizer Antibodies to madcam
JP2008515774A (en) * 2004-08-03 2008-05-15 ダイアックス コーポレイション hK1 binding protein
WO2006104978A2 (en) 2005-03-25 2006-10-05 Curagen Corporation Antibodies against the tenascin major antigens
US7480268B2 (en) 2005-07-28 2009-01-20 Symbol Technologies, Inc. System and method for multiprotocol wireless communication
AU2006316629A1 (en) 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with alpha 4 beta 7 integrin
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use

Also Published As

Publication number Publication date
AU2010226814A1 (en) 2011-09-29
WO2010107752A3 (en) 2011-01-20
US8454961B2 (en) 2013-06-04
US20150086563A1 (en) 2015-03-26
EP2408816A2 (en) 2012-01-25
CN103382222B (en) 2016-12-28
IL232008A (en) 2015-11-30
JO3615B1 (en) 2020-08-27
US8444981B2 (en) 2013-05-21
IL232009A0 (en) 2014-05-28
US20100254975A1 (en) 2010-10-07
AR075882A1 (en) 2011-05-04
CA2754113A1 (en) 2010-09-23
NZ595464A (en) 2013-08-30
MX338969B (en) 2016-05-06
SG10201801337WA (en) 2018-03-28
US8871490B2 (en) 2014-10-28
KR20130067314A (en) 2013-06-21
US9499620B2 (en) 2016-11-22
PE20120497A1 (en) 2012-05-14
CO6501170A2 (en) 2012-08-15
CR20110544A (en) 2011-12-07
EP2408816B1 (en) 2019-09-04
US8454962B2 (en) 2013-06-04
MY162752A (en) 2017-07-14
EA034783B1 (en) 2020-03-20
MX357213B (en) 2018-06-29
JP5980384B2 (en) 2016-08-31
TW201418281A (en) 2014-05-16
JP5775615B2 (en) 2015-09-09
ES2751946T3 (en) 2020-04-02
CA2851737A1 (en) 2010-09-23
KR101391472B1 (en) 2014-05-07
KR20110128948A (en) 2011-11-30
PE20160553A1 (en) 2016-05-18
JP2012520679A (en) 2012-09-10
TWI477511B (en) 2015-03-21
TW201036626A (en) 2010-10-16
IL239965A0 (en) 2015-08-31
US20130302354A1 (en) 2013-11-14
WO2010107752A2 (en) 2010-09-23
SG10201400798VA (en) 2014-07-30
MX2014013424A (en) 2015-07-29
MY184957A (en) 2021-04-30
CN102388068B (en) 2015-05-20
CA2754113C (en) 2014-08-05
MX357211B (en) 2018-06-29
CA2851737C (en) 2019-01-08
UY32501A (en) 2010-04-30
IL214868A (en) 2015-08-31
CN102388068A (en) 2012-03-21
JP2015214563A (en) 2015-12-03
CN103382222A (en) 2013-11-06
IL239965A (en) 2016-10-31
IL232008A0 (en) 2014-05-28
JP5498566B2 (en) 2014-05-21
IL214868A0 (en) 2011-11-30
EA201171148A1 (en) 2012-04-30
ZA201107279B (en) 2012-12-27
US20170275365A1 (en) 2017-09-28
TN2011000433A1 (en) 2013-03-27
US20120183561A1 (en) 2012-07-19
KR101346530B1 (en) 2013-12-31
CL2014000400A1 (en) 2014-08-29
MA33213B1 (en) 2012-04-02
SG174344A1 (en) 2011-11-28
IL232009A (en) 2015-11-30
US20120177662A1 (en) 2012-07-12
AU2010226814B2 (en) 2013-05-16
MX2011009897A (en) 2011-12-08
CL2011002306A1 (en) 2012-01-13
JP2014140372A (en) 2014-08-07
TWI466681B (en) 2015-01-01
HK1168116A1 (en) 2012-12-21

Similar Documents

Publication Publication Date Title
CL2014000401A1 (en) Antigen binding protein specific for the alpha4beta7 heterodimer; and composition comprising it (div.sol.no 2306-11).
CY2021027I1 (en) ANTI-CD20 ANTIBODY PREPARATION
CY2019004I1 (en) MODIFIED ANTI-IL-23P19 ANTIBODIES
IL269201A (en) Glycosylated antibodies
PL3059246T3 (en) Modified antibody constant region
IL214996A (en) Isolated antibody that binds a bmca polypeptide, a pharmaceutical composition comprising the same and uses thereof
DK2234600T3 (en) ANTIBODY FORMULATION
BRPI0921469A2 (en) binding proteins that inhibit interaction with the vegf-a receptor
BRPI0807991A2 (en) PREPARED ANTI-IL-23R ANTIBODIES.
CR10705A (en) ANTIBODIES FOR LYMPHOTOXINE-ALFA
IL226343A0 (en) Monoclonal antibodies against the rgm a protein and uses thereof
BRPI0918947A2 (en) antibody fusion protein
DK2066695T3 (en) ANTI-myostatin ANTIBODIES
BRPI0923231A2 (en) anti-cmet antibody.
BRPI0911922A2 (en) interactive input system and lighting set for the same
DK2171053T3 (en) Natriuretic polypeptides
BRPI0923199A2 (en) methods and compositions for detecting complement-fixing antibodies.
EP2276499A4 (en) RECOMBINANT DESAMIDED GLIADINE ANTIGEN
BRPI0814111A2 (en) CYTOTOXIC MONOCLONAL ANTIBODY
BRPI0817427A2 (en) Anti-bst2 antibody
DK2150276T3 (en) ANTIBODIES BINDING TO AN INTRACELLULAR PRL-1 OR PRL-3 POLYPEPTIDE
FR2903733B1 (en) TURBOMOTEUR FOR AIRCRAFT.
BRPI0814127A2 (en) IMMUNEGENIC POLYPEPTIDES AND MONOCLON ANTIBODIES
NL2002173A1 (en) Synthetic Aviation Fuel.
FR2919810B1 (en) FLYING OBJECT.